Zhi Jiang

Mrs. Zhi Jiang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in ESMO Open
Verified
Journal Article
Open access
YXY. Xiao
Y. Xiao
HWH. Wang
H. Wang
YTY. Tang
Y. Tang
JYJ. Yan
J. Yan
LCL. Cao
L. Cao
ZJZhi Jiang
Zhi Jiang
Diabetes is considered as an established risk factor for cancer development. However, the link between diabetes among cancer survivors remains inconclusive. The hypothesis of this study was to assess the hazard ratio (HR) of incidence of diabetes in cancer survivors compared with the HR in the general population. A comprehensive literature search was performed in PubMed, Embase, and the Cochrane Library from database inception to 15 December 2020 for population-based cohort studies. Summary effect estimates were combined using random-effects models. We also performed subgroup analyses to test sources of heterogeneity and the stability of the results stratified by various study and participant characteristics. Thirteen population-based cohort studies involving 1 686 595 participants were analyzed. The HR for the development of diabetes in cancer survivors was 1.39 [95% confidence interval (CI) 1.29-1.50; I2 = 82.3%; P < 0.001] compared with that in noncancer controls, among which survivors of hematological, gynecologic, breast, colorectal and urinary tract cancer (all P < 0.05) showed consistent significant results, whereas no significant increased risk was observed for other cancer types. The effects were more prominent in populations of shorter cancer survival duration (10 years) had a relatively higher risk of diabetes (HR 1.54, 95% CI 1.34-1.77) than those with a shorter follow-up period. In this large pooled analysis of population-based cohorts, evidence supports the hypothesis that the risk of developing diabetes is increased in cancer survivors compared with the general population. We should interpret the results with caution for considerable interstudy heterogeneity. However, health policy makers should take this as a challenge for the early prevention and effective intervention of diabetes.

25 May 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
JSJinchao Si
Jinchao Si
WLWei Li
Wei Li
XLXin Li
Xin Li
LCLixing Cao
Lixing Cao
ZCZhiqiang Chen
Zhiqiang Chen
ZJZhi Jiang
Zhi Jiang
The occurrence of temozolomide (TMZ) resistance is the main challenge in the management of glioma patients. Heparanase can mediate the secretion and function of exosomes, which are considered to be a promising molecular delivery system for cancer therapy. Therefore, this study aimed to investigate whether Heparanase-mediated delivery of exosomes was related to the TMZ resistance of glioma. Heparanase was up-regulated in TMZ-resistant glioma cells, and overexpression of Heparanase led to increased resistance of U87 cells to TMZ, while knockdown of Heparanase led to increased sensitivity of TMZ-resistant U251 cells (U251R) cells to TMZ. Heparanase promoted the secretion of exosomes from glioma cells, and co-culture with exosomes derived from Heparanase knockdown U251R cells partly restored the sensitivity of U251 cells to TMZ compared with exosomes derived from si-control transfected U251R cells. It was identified by circRNA microarrays that hsa_circ_0042003 was up-regulated in exosomes derived from U251R, which could be positively regulated by Heparanase. U251R cell-derived exosomal hsa_circ_0042003 conferred the resistance of U251 cells to TMZ. In vivo studies also showed that U251R cell-derived exosomes induced resistance of U251 cells to TMZ, and the combination of tail-injected exosomal si-Heparanase or eoxosomal si-hsa_circ_0042003 and intraperitoneal TMZ applied to nude mice abolished TMZ-resistance. Heparanase mediated the transfer of exosomal hsa_circ_0042003 from TMZ-resistant glioma cells to drug-sensitive cells, which contributed to the chemoresistance of glioma to TMZ.

4 March 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
ZYZhanfeng Yang
Zhanfeng Yang
JZJingjing Zhang
Jingjing Zhang
DLDanghui Lu
Danghui Lu
YSYan Sun
Yan Sun
XZXinyong Zhao
Xinyong Zhao
ZJZhi Jiang
Zhi Jiang
Background: Circular RNAs (circRNAs) have been shown to play a crucial role in tumorigenesis. In this study, we investigated the function of hsa_circ_0137008 and its underlying molecular mechanism in colorectal cancer (CRC). Methods: Gene expression was conducted by quantitative real-time PCR or western blot. Functional experiments were performed by cell count kit-8, colony formation assay, wound healing, and transwell assays. Luciferase reporter assay and RNA pull-down assay were performed to investigate the molecular mechanism of hsa_circ_0137008 in CRC. In addition, the xenograft tumor model was applied to determine the role of hsa_circ_0137008 in vivo. Results: Downregulation of hsa_circ_0137008 was observed in CRC tissues and cell lines. Functionally, overexpression of hsa_circ_0137008 inhibited the proliferation of CRC cells, as indicated by the inhibition of proliferative protein expression (Ki67 and PCNA), reduced cell viability and colony formation ability. Upregulation of hsa_circ_0137008 suppressed the migration, invasion, and epithelial to mesenchymal transition (EMT) of CRC cells. Mechanically, hsa_circ_0137008 negatively regulated the expression of microRNA-338-5p (miR-338-5p). Furthermore, hsa_circ_0137008 abated the miR-338-5p mediated promotion on CRC cell progression. Tumor suppressive function of hsa_circ_0137008 was validated in vivo. Conclusion: These findings highlighted the fact that overexpression of hsa_circ_0137008 inhibited the progression of CRC via sponging miR-338-5p, suggesting that hsa_circ_0137008/miR-338-5p axis is a principal regulator of CRC tumorigenesis.

14 August 2024 in International Journal of Surgery
Verified
Journal Article
Open access
WWWei Wang
Wei Wang
ZMZu-Bing Mei
Zu-Bing Mei
YCYajie Chen
Yajie Chen
JJJian Jiang
Jian Jiang
YQYanli Qu
Yanli Qu
ZJZhi Jiang
Zhi Jiang
Background: Mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) cancers are associated with an increased number of somatic mutations, which can render tumors more susceptible to immune checkpoint blockade. However, a comprehensive evaluation of the efficacy profile of immune checkpoint inhibitors in this patient population across multiple cancer types is lacking. This study aims to address this knowledge gap by synthesizing data from phase I–III clinical trials. Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Google Scholar from inception until June 2024. Eligible studies included randomized controlled trials (RCTs), nonrandomized comparative studies, and single-arm trials investigating immune checkpoint inhibitors in patients with dMMR/MSI-H advanced cancers. The primary outcome was objective response rate (ORR), and the secondary outcomes included disease control rate (DCR), 1-year, 2-year, and 3-year overall survival (OS) and progression-free survival (PFS) rates. Subgroup analyses were conducted for the primary outcome stratified by major study characteristics. Results: Of the 10 802 identified studies, 19 trials in 25 studies totaling 2052 participants met the inclusion criteria and were included in the meta-analysis. The pooled ORR was 41.7% (95% CI, 35.7–47.7%). The pooled DCR was 68.9% (95% CI, 62.2–75.7%). The pooled 12-month, 24-month, and 36-month OS rates were 29.1% (95% CI, 19.9–38.3%), 35.8% (95% CI, 23.6–48.0%), and 35.8% (95% CI, 23.6–48.0%), respectively. The pooled 12-month, 24-month, and 36-month PFS rates were 46.4% (95% CI, 39.1–53.8%), 67.0% (95% CI, 55.2–78.8%), and 63.1% (95% CI, 37.3–88.9%), respectively. Conclusions: The study establishes the therapeutic potential of immune checkpoint inhibitors in dMMR/MSI-H advanced cancers, highlighting the importance of MSI status in this context. Further, head-to-head comparisons are needed to conclusively determine MSI’s predictive power relative to proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors.

27 February 2018 in Trials
Verified
Journal Article
Open access
PDF file
HGHuachan Gan
Huachan Gan
JLJinxuan Lin
Jinxuan Lin
ZJZhi Jiang
Zhi Jiang
QCQicheng Chen
Qicheng Chen
LCLixing Cao
Lixing Cao
CZChen Zhiqiang
Chen Zhiqiang
Most patients who undergo abdominal surgery recover bowel movements within a week; however, some suffer prolonged intestinal paralysis or postoperative ileus (POI) leading to complications, such as infection and intestinal adhesions, which can extend hospitalization and increase readmission rates, and consequently increasing healthcare costs. Chinese medicine is effective for accelerating the recovery of gastrointestinal function after abdominal surgery. Xiangbin prescription (XBP) is the standard prescription for this purpose in our hospital; however, randomized controlled trials of it have not yet been conducted. This double-blind, randomized controlled clinical trial aims to recruit patients who have undergone abdominal surgery and experienced postoperative dysmotility to evaluate the efficacy and safety of XBP for preventing POI and accelerating recovery. The research will tackle the common problem of slow recovery of gastrointestinal function after surgery. The participants will be patients who undergo laparoscopic radical resection of rectal carcinoma or laparoscopic panhysterectomy of a benign lesion. Primary outcome measures will be time to first flatus, defecation, normal bowel sounds, and liquid/semi-liquid/general diet. Good Clinical Practice (GCP) standards of efficacy and safety will also be evaluated, along with objective investigation of the mechanism of action of ghrelin. This pivotal trial will be a standardized, scientific, clinical trial designed to evaluate the use of XBP for the recovery of gastrointestinal function after surgery, and it will conform to international standards for clinical trials for the recognition of traditional Chinese medicine. Chinese Clinical Trial Registry, ID: ChiCTR-TRC-14004156 . Registered on 3 January 2014.

28 October 2025 in International Journal of Surgery
Verified
Journal Article
Open access
ZJZhi Jiang
Zhi Jiang
XLXing Li
Xing Li
ZSZhuo Shao
Zhuo Shao
HTHailin Tang
Hailin Tang
JWJianwei Wu
Jianwei Wu
ZMZu-Bing Mei
Zu-Bing Mei
Background: Enhanced recovery after surgery (ERAS) protocols have transformed perioperative care in laparoscopic colorectal surgery, aiming to optimize patient outcomes. However, heterogeneity in reported outcomes across randomized controlled trials (RCTs) limits evidence synthesis and clinical application. A core outcome set (COS) is urgently needed to standardize outcome reporting and enhance research comparability. This study aims to systematically map outcomes reported in ERAS RCTs for laparoscopic colorectal surgery, providing a foundation for developing a tailored COS specific to this subfield. Methods: Following PRISMA guidelines, we searched PubMed, Embase, and the Cochrane Library for RCTs published from inception to April 2025, assessing ERAS protocols in laparoscopic colorectal surgery. Studies were included if they were RCTs comparing ERAS interventions with standard care or other ERAS variants. Data on study characteristics, interventions, and reported outcomes were extracted and categorized into domains using narrative synthesis. Outcome frequency and measurement variability were analyzed. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Results: From 57 included RCTs ( n = 7502 patients), 86 unique outcomes were identified across 9 domains: gastrointestinal recovery (25.6%, e.g., time to first flatus, 45.6% of studies), postoperative pain (18.6%, e.g., Visual Analogue Scale pain scores, 31.6%), hospital stay (14.0%, e.g., length of stay, 38.6%), postoperative complications (15.1%), physical function (9.3%), immune and inflammatory response (7.0%), patient-reported outcomes (4.7%), postoperative nausea and vomiting (3.5%), and economic outcomes (2.3%). Outcome definitions and measurement tools varied widely, with no consistent standardization. Conclusions: This study highlights heterogeneity in ERAS outcome reporting, emphasizing the need for a COS. The identified domains and outcomes provide a foundation for standardizing research, improving evidence quality, and guiding clinical practice.